دورية أكاديمية
أعرض في EDS

The fungicidal effectiveness of 2-Chloro-3-hydrazinylquinoxaline, a newly developed quinoxaline derivative, against Candida species.

التفاصيل البيبلوغرافية
العنوان: The fungicidal effectiveness of 2-Chloro-3-hydrazinylquinoxaline, a newly developed quinoxaline derivative, against Candida species.
المؤلفون: Alfadil A; Faculty of Medicine, Department of Clinical Microbiology and Immunology, King Abdulaziz University, Jeddah, Saudi Arabia.; Center of Research Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia., Ibrahem KA; Faculty of Medicine, Department of Clinical Microbiology and Immunology, King Abdulaziz University, Jeddah, Saudi Arabia., Alrabia MW; Faculty of Medicine, Department of Clinical Microbiology and Immunology, King Abdulaziz University, Jeddah, Saudi Arabia., Mokhtar JA; Faculty of Medicine, Department of Clinical Microbiology and Immunology, King Abdulaziz University, Jeddah, Saudi Arabia., Ahmed H; King Abdulaziz Hospital, Jeddah, Saudi Arabia.
المصدر: PloS one [PLoS One] 2024 May 10; Vol. 19 (5), pp. e0303373. Date of Electronic Publication: 2024 May 10 (Print Publication: 2024).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Antifungal Agents*/pharmacology , Antifungal Agents*/chemistry , Quinoxalines*/pharmacology , Quinoxalines*/chemistry , Candida*/drug effects , Microbial Sensitivity Tests*, Animals ; Mice ; Disease Models, Animal ; Candidiasis/drug therapy ; Candidiasis/microbiology ; Female
مستخلص: Background: Candida represents a prevalent fungal infection, notable for its substantial implications on morbidity and mortality rates. In the landscape of prospective treatments, quinoxaline derivatives emerge as a category of compact compounds exhibiting notable potential in addressing infections. These derivatives showcase promising antimicrobial efficacy coupled with favorable pharmacokinetic and safety characteristics.
Aims: The central aim of this investigation was to examine the antifungal characteristics of 2-Chloro-3-hydrazinylquinoxaline against diverse strains of Candida and Aspergillus in vitro. Additionally, we endeavored to assess the in vivo efficacy of 2-Chloro-3-hydrazinylquinoxaline using a murine model for oral candidiasis induced by C. albicans cells ATCC 10231.
Results: 2-Chloro-3-hydrazinylquinoxaline demonstrated noteworthy effectiveness when tested against various reference strains of Candida species. It exhibited heightened efficacy, particularly against Candida krusei isolates. However, its performance against Candida albicans, Candida tropicalis, Candida glabrata, Candida parapsilosis, and Candida auris isolates exhibited variability. Notably, 2-Chloro-3-hydrazinylquinoxaline manifests variable efficacy against Aspergillus fumigatus, Aspergillus niger, Aspergillus terreus and Aspergillus flavus and no effect against Aspergillus brasiliensis. In a murine model, 2-Chloro-3-hydrazinylquinoxaline exhibited significant efficacy in combating the C. albicans cells ATCC 10231 strain, underscoring its potential as a viable treatment option.
Conclusion: 2-Chloro-3-hydrazinylquinoxaline has demonstrated substantial potential in effectively addressing various Candida and Aspergillus species, showcasing dual attributes of antifungal and anti-inflammatory properties. However, to attain a more comprehensive understanding of its therapeutic capabilities, further investigations, incorporating additional tests and experiments, are imperative.
Competing Interests: NO authors have competing interests.
(Copyright: © 2024 Alfadil et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
References: Antibiotics (Basel). 2022 Jun 30;11(7):. (PMID: 35884131)
Sci Transl Med. 2012 Mar 21;4(126):126ra35. (PMID: 22440737)
Int J Antimicrob Agents. 2021 Mar;57(3):106283. (PMID: 33503451)
Microbiol Immunol. 2003;47(5):321-6. (PMID: 12825893)
Genes (Basel). 2018 Sep 19;9(9):. (PMID: 30235884)
Nat Prod Rep. 2012 Sep;29(9):1007-21. (PMID: 22786554)
Eur J Med Chem. 2012 Aug;54:87-94. (PMID: 22621841)
Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2. (PMID: 9455502)
Front Pharmacol. 2016 Mar 21;7:64. (PMID: 27047380)
Semin Respir Crit Care Med. 2015 Feb;36(1):3-16. (PMID: 25643267)
Perspect Medicin Chem. 2014 Aug 28;6:25-64. (PMID: 25232278)
Eur J Med Chem. 2015 Jun 5;97:664-72. (PMID: 25011559)
Clin Microbiol Rev. 2007 Jan;20(1):133-63. (PMID: 17223626)
Infect Drug Resist. 2023 Apr 18;16:2291-2296. (PMID: 37095779)
Antimicrob Agents Chemother. 2016 May 23;60(6):3433-44. (PMID: 27001812)
Nat Microbiol. 2019 Apr;4(4):565-577. (PMID: 30833727)
Expert Opin Drug Discov. 2020 Apr;15(4):397-401. (PMID: 31847616)
Elife. 2015 Feb 03;4:e00662. (PMID: 25646566)
Antimicrob Agents Chemother. 2015 Dec;59(12):7396-404. (PMID: 26392513)
المشرفين على المادة: 0 (Antifungal Agents)
0 (Quinoxalines)
تواريخ الأحداث: Date Created: 20240510 Date Completed: 20240510 Latest Revision: 20240512
رمز التحديث: 20240512
مُعرف محوري في PubMed: PMC11086890
DOI: 10.1371/journal.pone.0303373
PMID: 38728271
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0303373